| Heading: |
Cerliponase Alfa |
| Question ID: |
1784872 |
| UIN: |
38486 |
| House: |
Commons |
| Date tabled: |
2025-03-14 |
| Asking Member ID: |
5178 |
| Asking Member display name: |
Sally Jameson
|
| Asking Member handle: |
SallyJameson
|
| Asking Member Twitter reference: |
@SallyJameson
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of ensuring that a permanent access agreement is reached for Brineura as a treatment for patients with neuronal ceroid lipofuscinosis type 2 (CLN |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-03-26 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether cerliponase alfa, also known as Brineura, can be recommended for routine NHS funding, considering real-world evidence ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |